Detecting spinal cord lesions in multiple sclerosis using advanced MRI techniques
Official title: Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences: A Pilot Study
Run by University Hospital, Basel, Switzerland · NCT04819737 · Data updated 2026-11-12
This study is testing a new MRI technique to see if it can better detect spinal cord lesions in people with multiple sclerosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | July 18, 2022 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT04819737 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with multiple sclerosis who meet specific inclusion criteria and are part of the Swiss MS Cohort.
✕Probably not a fit
Patients with severe neurological, internal, or psychiatric diseases affecting the spinal cord, or those with contraindications for MRI, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a novel MRI sequence called averaged magnetization inversion recovery acquisitions (AMIRA) for detecting spinal cord lesions in patients with multiple sclerosis. The research focuses on assessing the sensitivity of this imaging technique and the agreement between different observers in identifying lesions. Additionally, it aims to determine the clinical value of AMIRA in real-world settings, leveraging its superior contrast and resolution for better diagnosis. Participants will undergo spinal cord MRI and complete a patient questionnaire as part of the evaluation process.
Why it matters
Potential benefit: If successful, this study could lead to improved detection of spinal cord lesions in multiple sclerosis, enhancing diagnosis and treatment planning.
How similar studies have gone: Other studies have shown promise in using advanced MRI techniques for detecting lesions in multiple sclerosis, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of multiple sclerosis according to established international criteria * Steroid free period: \> 4 weeks * Participation in the Swiss MS Cohort (SMSC) study Exclusion Criteria: * . History of severe (other) neurological, internal or psychiatric disease with SC affection * MRI-related exclusion criteria (questionnaire): 1. Paramagnetic and/or superparamagnetic foreign objects in the body (especially when located close to the SC) 2. Pacemaker 3. Claustrophobia 4. Pregnancy, lactation 5. Known hypersensitivity to gadolinium-based contrast media
Where it's running
-
University Hospital Basel, Department of Neurology
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Katrin Parmar, PD Dr. med. — University Hospital Basel, Department of Neurology
- Study coordinator: Katrin Parmar, PD Dr. med.
- Email: katrin.parmar@unibas.ch
- Phone: +41 61 83 65 214
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases
This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.
-
Can QSM MRI help tell MS from age-related brain changes in older adults
This study tests whether an advanced MRI technique called QSM can better differentiate MS-related brain lesions from age-related or small vessel changes in people aged 50–70.
-
Escalation versus induction therapy for relapsing MS starting after age 50
This project will test whether starting with stronger, highly effective treatments or beginning with moderate drugs and escalating later changes the risk of inflammatory relapses for people whose relapsing MS began after age 50.
-
Impact of a Palliative Care Model on Patient Knowledge and Attitudes
This study tests if a video about palliative care can help people with Multiple Sclerosis understand their treatment options better than just reading a pamphlet.
-
Observational study on CNS inflammatory demyelinating diseases in the Chinese population
This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.
-
C-CAR168 treatment for autoimmune diseases not responding to standard therapy
This study is testing a new treatment called C-CAR168 to see if it can help adults with autoimmune diseases that haven't improved with standard therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.